Combination of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and Dyslipidemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 138 participants.

Also called NCT03156842

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 138 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03156842
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03156842. Randomized; triple masking; primary purpose treatment. Start 2017-05-29 (actual); primary completion 2018-12-07 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Combination of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and Dyslipidemia
Acronym
FIRST
Condition
Essential Hypertension
Condition
Dyslipidemia
Intervention (Drug)
Fimasartan/Amlodipine, Rosuvastatin
Intervention (Drug)
Fimasartan/Amlodipine
Intervention (Drug)
Fimasartan, Rosuvastatin
Lead sponsor
Boryung Pharmaceutical Co., Ltd (class: industry)

Record details

Record id
cardio:ct-nct03156842
Content hash
2e7b1aa5b0cb3a5a0d2bfb9c38c55eb6b591cf69a9c3dd58f4526207fd4adb18